MDT

83.58

-0.61%↓

VEEV

225.8

+0.45%↑

105.71

+0.08%↑

WBA

10.98

-0.18%↓

CHE

548.09

-0.97%↓

MDT

83.58

-0.61%↓

VEEV

225.8

+0.45%↑

105.71

+0.08%↑

WBA

10.98

-0.18%↓

CHE

548.09

-0.97%↓

MDT

83.58

-0.61%↓

VEEV

225.8

+0.45%↑

105.71

+0.08%↑

WBA

10.98

-0.18%↓

CHE

548.09

-0.97%↓

MDT

83.58

-0.61%↓

VEEV

225.8

+0.45%↑

105.71

+0.08%↑

WBA

10.98

-0.18%↓

CHE

548.09

-0.97%↓

MDT

83.58

-0.61%↓

VEEV

225.8

+0.45%↑

105.71

+0.08%↑

WBA

10.98

-0.18%↓

CHE

548.09

-0.97%↓

Kodu・Aktsiate loetelu・Bristol-Myers Squibb Co.

Bristol-Myers Squibb Co.

Suletud

SektorTervishoid

48.68 0.35

Osta Müü

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

46.98

Max

48.84

Põhinäitajad
By Trading Economics
Sissetulek	-1.1B 76M
Müük	442M 12B
P/E Sektori keskmine	14.05 57.333
Aktsiakasum	1.67
Dividenditootlus	5.04
Kasumimarginaal	0.616
Töötajad	34,100
EBITDA	-1.9B 2.6B

Soovitused
By TipRanks
Soovitused	Neutraalne
12 kuu keskmine prognoos	+18.22% upside

Dividendid
By Dow Jones
Dividenditootlus Sektori keskmine	5.04% 2.63%
Järgmine dividendimakse kuupäev	1. mai 2025
Järgmine aktsia dividendi kuupäev (ex-date)	4. juuli 2025

Turustatistika
By TradingEconomics
Turukapital	-21B 100B
Eelmine avamishind	48.33
Eelmine sulgemishind	48.68

Tehniline skoor

By Trading Central

Kindlus

Neutral Evidence

47.54 / 48.82 Toetus ja vastupanu

Bristol-Myers Squibb Co. Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

24. apr 2025, 11:32 UTC

Tulu

Bristol Myers Squibb Swings to Profit in 1Q, Increases Fiscal Year Guidance

11. märts 2025, 10:13 UTC

Suurimad hinnamuutused turgudel

Omandamised, ülevõtmised, äriostud

2seventy Bio Shares Soar Premarket on Deal to be Acquired by Bristol Myers

11. märts 2025, 10:13 UTC

Suurimad hinnamuutused turgudel

Omandamised, ülevõtmised, äriostud

2seventy Bio Shares Soar Premarket on Deal to be Acquired by Bristol Myers

24. apr 2025, 21:24 UTC

Peamised uudised

Tulu

Bristol Myers Reports Better-Than-Expected Earnings. The Future Is Cloudy. -- Barrons.com

24. apr 2025, 14:15 UTC

Peamised uudised

Tulu

Bristol Myers Squibb Shares Sink Despite Better-than-Expected Earnings. The Future Is Cloudy. -- Barrons.com

24. apr 2025, 12:37 UTC

Market Talk

Tulu

Bristol Myers Squibb Raises Guidance, But Any Pharma-Sector Tariffs Could be a Drag -- Market Talk

24. apr 2025, 11:17 UTC

Tulu

Bristol Myers Squibb Swings to Profit in 1Q, Increases FY Guidance

24. apr 2025, 11:13 UTC

Peamised uudised

Tulu

Bristol Myers Squibb Posts Better-than-Expected Earnings, Raises Full-Year Guidance -- Barrons.com

24. apr 2025, 10:59 UTC

Tulu

Bristol Myers Squibb: Raised 1Q Rev Outlook Reflecting Strong Performance of Growth Portfolio, Better-Than-Expected 1Q Legacy Portfolio Sales and Favorable Impact of About $500M Related to Forex Rates >BMY

24. apr 2025, 10:59 UTC

Tulu

Bristol Myers Squibb Latest 1Q Includes Acquired IPRD Charge of $188M >BMY

24. apr 2025, 10:59 UTC

Tulu

Bristol Myers Squibb 1Q U.S. Revenue Fell 7% to $7.87B >BMY

24. apr 2025, 10:59 UTC

Tulu

Bristol Myers Squibb: Guidance Revisions Include Estimated Impact of Current Tariffs on U.S. Products Shipped to China, but Do Not Account for Any Potential Pharmaceutical Sector Tariffs >BMY

24. apr 2025, 10:59 UTC

Tulu

Bristol Myers Squibb 1Q Growth Portfolio Revenue Rose 16% to $5.56B >BMY

24. apr 2025, 10:59 UTC

Tulu

Bristol Myers Squibb: Growth Portfolio Revenue Increase Primarily Driven by Opdivo, Breyanzi, Reblozyl and Camzyos and Reflects Strong Early U.S. Launch of Cobenfy >BMY

24. apr 2025, 10:59 UTC

Tulu

Bristol Myers Squibb 1Q Adjusted Gross Margin 73.1% >BMY

24. apr 2025, 10:59 UTC

Tulu

Bristol Myers Squibb 1Q International Revenue Fell 2% to $3.33B >BMY

24. apr 2025, 10:59 UTC

Tulu

Bristol Myers Squibb: Legacy Portfolio Rev Decline Driven by Continued Generic Impact on Revlimid, Pomalyst, Sprycel and Abraxane, as Well as Impact From U.S. Medicare Part D Redesign >BMY

24. apr 2025, 10:59 UTC

Tulu

Bristol Myers Squibb 1Q Legacy Portfolio Rev Fell 20% to $5.64B >BMY

24. apr 2025, 10:59 UTC

Tulu

Bristol Myers Squibb 1Q Adj EPS $1.80 >BMY

24. apr 2025, 10:59 UTC

Tulu

Bristol Myers Squibb Raises 2025 View To Rev $45.8B-$46.8B Vs Prior View $45.5B >BMY

24. apr 2025, 10:59 UTC

Tulu

Bristol Myers Squibb 1Q Gross Margin 72.9% >BMY

24. apr 2025, 10:59 UTC

Tulu

Bristol Myers Squibb Raises 2025 View To Adj EPS $6.70-Adj EPS $7.00 Vs Prior View $6.55-$6.85 >BMY

24. apr 2025, 10:59 UTC

Tulu

Bristol Myers Squibb 1Q Rev $11.2B >BMY

24. apr 2025, 10:59 UTC

Tulu

Bristol Myers Squibb 1Q EPS $1.20 >BMY

24. apr 2025, 10:59 UTC

Tulu

Bristol-Myers Squibb 1Q Adj EPS $1.80 >BMY

24. apr 2025, 10:59 UTC

Tulu

Bristol-Myers Squibb 1Q Rev $11.2B >BMY

24. apr 2025, 10:59 UTC

Tulu

Bristol-Myers Squibb 1Q Net $2.46B >BMY

24. apr 2025, 10:59 UTC

Tulu

Bristol-Myers Squibb Sees FY Adj EPS $6.70-Adj EPS $7.00 >BMY

24. apr 2025, 10:59 UTC

Tulu

Bristol-Myers Squibb 1Q EPS $1.20 >BMY

14. märts 2025, 09:30 UTC

Peamised uudised

Big Pharma Walked Away From Mental Health. Why Some Are Coming Back. -- Heard on the Street -- WSJ

Võrdlus sarnastega

Hinnamuutus

Bristol-Myers Squibb Co. Prognoos

Hinnasiht

By TipRanks

18.22% tõus

12 kuu keskmine prognoos

Keskmine 57.56 USD 18.22%

Kõrge 70 USD

Madal 36 USD

Põhineb 19 Wall Streeti analüütiku instrumendi Bristol-Myers Squibb Co. 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Neutraalne

19 ratings

Osta

Hoia

Müü

Põhineb 19 analüütiku instrumendi Bristol-Myers Squibb Co. aktsia reitingul - viimase 3 kuu andmed.

Tehniline skoor

By Trading Central

47.54 / 48.82Toetus ja vastupanu

The bullish and bearish events are balanced.

All events are bearish.

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

Ettevõttest Bristol-Myers Squibb Co.

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia. It also provides Yervoy for the treatment of patients with unresectable or metastatic melanoma; Empliciti for the treatment of multiple myeloma; Abecma for the treatment of relapsed or refractory multiple myeloma; Reblozyl for the treatment of anemia; Opdualag for the treatment of unresectable or metastatic melanoma; and Zeposia to treat relapsing forms of multiple sclerosis. In addition, the company offers Breyanzi for the treatment of relapsed or refractory large B-cell lymphoma; Onureg for the treatment of AML; Inrebic for the treatment of myelofibrosis; Camzyos for the treatment of symptomatic obstructive HCM to enhance functional capacity and symptom; Sotyktu for the treatment of moderate-to-severe plaque psoriasis; Augtyro for the treatment of locally advanced or metastatic ROS1-positive NSCLC; Revlimid, an oral immunomodulatory drug for the treatment of multiple myeloma; and Abraxane to treat breast cancer, NSCLC and pancreatic cancer. It sells products to wholesalers, distributors, pharmacies, retailers, hospitals, clinics, and government agencies. The company was formerly known as Bristol-Myers Company. Bristol-Myers Squibb Company was founded in 1887 and is headquartered in Princeton, New Jersey.